In this update, Ashley Yocum, PhD, executive research strategy lead of the Beat AML Master Trial at the Leukemia & Lymphoma Society, provides insights into the Beat AML Master Trial, a precision medicine initiative operating across 12 academic sites and enrolling over 1600 patients. The trial focuses on upfront therapies using venetoclax and azacitidine for specific mutations, prioritizing newly diagnosed patients with challenging mutations like TP53. Additionally, the trial has expanded to include relapsed/refractory patients, introducing novel agents to enhance survival rates, especially for older AML patients.